USA – Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

Emergency use authorisations for both Moderna and Pfizer/BioNTech's bivalent mRNA COVID-19 vaccines have been amended by the US Food and Drug Administration (FDA) to simplify the vaccination schedule for most individuals.

The current bivalent vaccines, targeting the original and omicron BA.4/BA.5 strains, can now be used for all doses administered to individuals aged six months and older, including for an additional dose or doses for certain populations.

Each vaccine now has one fact sheet for healthcare providers and one for recipients and caregivers, rather than different fact sheets for the various authorised age groups…